TLP Group’s Astria Therapeutics ATXS Stock Holding History

TLP Group’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-432	Closed	-$160K	–	267
2016 Q3	$160K	Buy	+432	New	+$114K	0.17%	96

Other funds holding ATXS

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TLP Group's ATXS Position: Q4 2016 in Review

TLP Group sold out of Astria Therapeutics (ATXS) in Q4 2016, closing a stake of 432 shares — an estimated $160K sold.

TLP Group first reported a position in ATXS in Q3 2016 and held it in 1 quarter. The position peaked at $160K in Q3 2016. 26 funds tracked by Wall St. Rank hold ATXS as of Q4 2016.

TLP Group reported no remaining Astria Therapeutics position as of Q4 2016 after selling out during the quarter.
TLP Group sold 432 Astria Therapeutics shares in Q4 2016, an estimated $160K.
TLP Group first reported a position in Astria Therapeutics in Q3 2016 and held it in 1 quarter.
TLP Group's Astria Therapeutics position peaked at $160K in Q3 2016.
26 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2016.

Based on TLP Group's 13F filing for Q4 2016, filed 2 Feb 2017.